Heiden hired as AMAG CEO
This article was originally published in Scrip
AMAG Pharmaceuticals has enlisted William Heiden as president and CEO and a member of the board of directors. Frank Thomas, who has served as interim CEO of the company since November 2011, will return to his role of executive vice-president and COO. Mr Heiden is the former president and CEO of GTC Biotherapeutics, where he will continue to serve as chair.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.